Cardium is focused on the acquisition and strategic development of new and

innovative bio-medical product opportunities and businesses that have the

potential to address significant unmet medical needs. Cardium’s current

CARDIUM
investment portfolio includes the Tissue Repair Company, Cardium Biologics,
and the Company’s in-house MedPodium™ healthy lifestyle product platform.
The Company’s lead product candidates include Excellagen™ topical gel for
wound care management, and Generx® DNA-based angiogenic biologic for MEDIC AL O P P OR T UNI T IE S P OR T F OL IO
patients with coronary artery disease. Consistent with its capital-efficient
business model, Cardium continues to actively evaluate new technologies and
business opportunities. In July 2009, Cardium completed the sale of its InnerCool
Therapies medical device business to Philips, the first asset monetization from
the Company’s biomedical investment portfolio.

CORPORATE MILESTONES
October 2005 - Acquired a portfolio of biologic growth factors from
the Schering AG Group for potential use in treating ischemic and other
cardiovascular conditions, including Generx®, a product candidate being
developed for patients with chronic myocardial ischemia
March 2006 - Acquired technologies and products of InnerCool Therapies,
Inc., a medical technology company in the emerging field of therapeutic
hypothermia or patient temperature modulation
August 2006 - Acquired Tissue Repair Company, a company focused
on the development of therapeutics for the potential treatment of
chronic wounds and other tissue injuries, including our Excellagen™ and
Excellarate™ product candidates
July 2009 - Sold InnerCool Therapies to Royal Philips Electronics (NYSE: PHG)
The Generx product
December 2009 - Filed application for FDA 510(k) clearance for Excellagen™ candidate is designed
June 2010 - Announced plans to initiate clinical study at three leading to simulate and promote the
medical centers in Moscow for Cardium’s Generx® product candidate growth of microvascular circulation in
the heart following a one-time intracoronary
November 2010 - Launched the MedPodium™ modern lifestyle product administration from a standard cardiac
line (www.medpodium.com), a portfolio of premium, science-based, easy catheter during an outpatient procedure.
to use nutraceuticals, metabolics and aesthetics designed to promote
health and well-being
Actively seeking acquisition and strategic partnerships opportunities

Generx®/Cardiovascular Excellagen™/Wound Healing & Repair NYSE Amex Ticker Symbol CXM
Large cardiovascular market Diabetic foot ulcers (DFU) remain
P opportunity on global basis P significant unmet medical need in U.S. Current Stock Price (1/19/2011) $0.40/share
and worldwide
16.7 million people around the 15% of 24 million diabetic patients
P globe die of cardiovascular P in the U.S. will develop in a foot ulcer Average Daily Trading Volume (3 months) 550,000 Shares/Day
diseases each year each year
80% of future increase in Approximately 1.0 million patients
P coronary heart disease P will develop DFU each year (20% will Approx Market Capitalization $31.0 Million
mortality will occur outside U.S. require amputation)
Most advanced DNA-based DFU’s represent a $1.4 billion market
P cardiovascular disease biologic P opportunity in U.S. Management Ownership 9.2%
in the world
Planned registration pathway 2007 first single $1.0 billion advanced
P offers potential for accelerated
commercialization
P would care product (KCI / V.A.C.) NYSE AMEX: CXM
PRODUCT PIPELINE
PRODUCT PRECLINICAL PHASE 1/2 PHASE 2B/3 PHASE 3 COMMERCIAL
Excellagen Formulated Collagen
™
510(k) REGISTRATION PATHWAY
WOUND HEALING Wound Care Dressings
& REPAIR Excellarate [Ad5PDGF-B] DNA-
™

Based Wound Healing DIABETIC FOOT ULCERS

Generx® [Ad5FGF-4] DNA-Based
CARDIOVASCULAR Angiogenic Therapy for Heart Disease CORONARY ARTERY DISEASE

NUTRACEUTICALS, MedPodium™ Modern Lifestyle COMMERCIALIZATION

METABOLICS & AESTHETICS Product Line
PRODUCT DEVELOPMENT PROGRAMS
Excellagen™ is a highly-refined fibrillar bovine Type I collagen-based
topical gel (2.6% collagen concentration). Based on the pending 510(k)
FDA submission, Excellagen™ will be indicated for the management of
CARDIUM
MEDIC AL O P P OR T UNI T IE S P OR T F OL IO
wounds, including partial and full thickness wounds, pressure ulcers,
diabetic ulcers, chronic vascular ulcers and certain other wounds, such
as surgical and trauma wounds.

Generx® (alferminogene tadenovec, Ad5FGF-4) is a DNA-based angiogenic

growth factor therapeutic product candidate representing a new class
RECENT DEVELOPMENTS
of cardiovascular biologic, as a potential treatment for patients with
advanced coronary artery disease. Generx® is designed to stimulate • Application for Food and Drug
and promote the growth of supplemental collateral vessels to enhance Administration (FDA) 510(k) U.S.
marketing clearance of Excellagen™, a
myocardial blood flow (perfusion) following a one-time intracoronary
professional-use formulated collagen
administration from a standard cardiac infusion catheter in patients
gel for wound care management of
who have insufficient blood flow due to atherosclerotic plaque build-up diabetic ulcers, as well as other types
in the coronary arteries. Generx® is currently being developed as a cost of wounds;
effective front-line therapy for patients with coronary artery disease in • Agreement with bioRASI to assist in
newly-industrializing countries who often do not have access to costly a planned late-stage clinical study
advanced care procedures such as coronary angioplasty and stenting, and commercialization activities for
or cardiac bypass surgery. Cardium’s cardiovascular biologic
candidate, Generx®, in Russia, as
Excellarate™ is a collagen-based topical gel employing TRC’s Gene well as in potentially other newly
Activated Matrix technology to locally stimulate the release of platelet- industrializing markets
derived growth factor-B protein (PDGF-B), an important key in the • Launch of MedPodium™ modern
human body’s wound healing process. Sustained, localized micro- lifestyle brand initiative, a portfolio
release of PDGF-B by a patient’s own cells directly at the wound site is of premium, science-based, easy-to-
believed to stimulate angiogenesis and granulation tissue formation use nutraceuticals, metabolics and
through the recruitment and proliferation of cells such as monocytes, aesthetics designed to promote health
fibroblasts and endothelial cells. Cardium’s Excellarate™ product and well-being
candidate is initially being developed to facilitate wound closure in • Market launch of the new weight
non-healing diabetic foot ulcers. management product, Linée (Appexium
150 mg) designed to help manage
MedPodium™, a portfolio of premium, science-based, easy-to-use appetite and hunger
nutraceuticals, metabolics and aesthetics, is based on key ingredients • Continued identification and evaluation
that have been well characterized and scientifically shown to be capable of innovative and capital-efficient
of promoting healthy lifestyle interests such as enhancing energy, product opportunities and strategic
cognition, mood, sleep, weight management, fitness and aesthetics. partnership opportunities

PRODUCT DEVELOPMENT

EXCELLAGEN
Fibrillar Bovine Collagen Topical Gel (2.6%)
for Wound Care Management

CARDIUM CARDIUM THERAPEUTICS, INC.

MEDICAL OPPORTUNITIES PORTFOLIO
12255 El Camino Real
INVESTOR RELATIONS
Bonnie Ortega
This Fact Sheet may contain forward-looking statements, including comments
concerning product candidates, clinical trials and product development programs,
registration pathways, evaluation of potential opportunities, the level of corporate
Suite 250 Director, Investor Relations expenditures, the assessment of Cardium’s technology by potential corporate partners,
San Diego, CA 92130 (858) 436-1018 capital market conditions, timing of events, cash consumption and other subjects. Actual
(858) 436-1000 email: bortega@cardiumthx.com results could differ materially from these forward-looking statements for many reasons,
Fax: (858) 436-1001 including the risks described under “Risk Factors” in the Company’s Annual Report on
http://www.cardiumthx.com Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange
Commission. No guarantee about future results, performance or achievements can
http://www.medpodium.com be made. Neither Cardium nor its agents intend to update any of the forward-looking
statements after the date of this presentation to conform them to actual results or to
changes in expectations.